

Victor M Rivera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12041238/publications.pdf>

Version: 2024-02-01

64
papers

8,212
citations

94433

37
h-index

123424

61
g-index

64
all docs

64
docs citations

64
times ranked

8682
citing authors

#	ARTICLE	IF	CITATIONS
1	AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. <i>Cancer Cell</i> , 2009, 16, 401-412.	16.8	1,050
2	Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias. <i>New England Journal of Medicine</i> , 2012, 367, 2075-2088.	27.0	668
3	A humanized system for pharmacologic control of gene expression. <i>Nature Medicine</i> , 1996, 2, 1028-1032.	30.7	538
4	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7535-7540.	7.1	515
5	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	1.4	392
6	Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4701-4719.	6.4	315
7	Regulated Delivery of Therapeutic Proteins After in Vivo Somatic Cell Gene Transfer. <i>Science</i> , 1999, 283, 88-91.	12.6	313
8	Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 690-699.	4.1	289
9	Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4948-4964.	6.4	277
10	Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2008, 26, 361-367.	1.6	273
11	The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. <i>Clinical Cancer Research</i> , 2016, 22, 5527-5538.	7.0	263
12	Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. <i>Blood</i> , 2005, 105, 1424-1430.	1.4	258
13	Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2012, 30, 78-84.	1.6	238
14	A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 2756-2762.	7.0	233
15	Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance. <i>Chemical Biology and Drug Design</i> , 2011, 77, 1-11.	3.2	231
16	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 612-621.	10.7	214
17	Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. <i>Blood</i> , 2004, 104, 2532-2539.	1.4	181
18	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. <i>Clinical Cancer Research</i> , 2014, 20, 5745-5755.	7.0	137

#	ARTICLE	IF	CITATIONS
19	Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1028-1035.	4.1	135
20	Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen. <i>Chemical Biology and Drug Design</i> , 2011, 78, 999-1005.	3.2	127
21	Long-Term Inducible Gene Expression in the Eye via Adeno-Associated Virus Gene Transfer in Nonhuman Primates. <i>Human Gene Therapy</i> , 2005, 16, 178-186.	2.7	115
22	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1672-1687.	9.4	112
23	Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye. <i>Molecular Therapy</i> , 2002, 6, 238-242.	8.2	94
24	Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1059-1071.	4.1	92
25	A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 1428-1434.	7.0	89
26	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. <i>Blood</i> , 2016, 127, 703-712.	1.4	87
27	Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. <i>Oncotarget</i> , 2015, 6, 32646-32655.	1.8	65
28	Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 1309-1335.	3.0	64
29	Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1315-1323.	2.3	58
30	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. <i>Blood</i> , 2016, 127, 1870-1880.	1.4	58
31	A Phase I Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings. <i>Blood</i> , 2010, 116, 210-210.	1.4	53
32	Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, <i>Drosophila</i> and mice. <i>Oncotarget</i> , 2016, 7, 29011-29022.	1.8	51
33	Regulated expression of erythropoietin from an AAV vector safely improves the anemia of β^2 -thalassemia in a mouse model. <i>Molecular Therapy</i> , 2003, 7, 493-497.	8.2	50
34	A System for Small-Molecule Control of Conditionally Replication-Competent Adenoviral Vectors. <i>Molecular Therapy</i> , 2002, 5, 195-203.	8.2	49
35	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine. <i>Journal of Clinical Oncology</i> , 2010, 28, 4554-4561.	1.6	47
36	Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1959-1968.	4.1	46

#	ARTICLE	IF	CITATIONS
37	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014, 124, 3135-3135.	1.4	43
38	The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 5250-5254.	1.4	37
39	Targeting HER2 Exon 20 Insertion Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. <i>Cancer Research</i> , 2021, 81, 5311-5324.	0.9	31
40	Controlling Gene Expression Using Synthetic Ligands. <i>Methods</i> , 1998, 14, 421-429.	3.8	28
41	Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. <i>International Journal of Oncology</i> , 2012, 41, 425-432.	3.3	28
42	Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. <i>Molecular Therapy</i> , 2006, 13, 167-174.	8.2	24
43	Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. <i>Clinical Cancer Research</i> , 2018, 24, 5321-5334.	7.0	24
44	Rapamycin-regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer. <i>Molecular Therapy</i> , 2007, 15, 912-920.	8.2	21
45	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. <i>Oncotarget</i> , 2018, 9, 29654-29664.	1.8	20
46	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	6.2	20
47	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 849-860.	2.3	18
48	Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1369-1377.	2.3	18
49	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3743-3748.	2.2	17
50	Regulation of gene expression by synthetic dimerizers with novel specificity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 3181-3184.	2.2	13
51	Dimerizer-Mediated Regulation of Gene Expression In Vivo. <i>Cold Spring Harbor Protocols</i> , 2012, 2012, pdb.prot070144-pdb.prot070144.	0.3	13
52	[15] Regulation of gene expression with synthetic dimerizers. <i>Methods in Enzymology</i> , 1999, 306, 263-281.	1.0	12
53	Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants. <i>Blood</i> , 2013, 122, 3992-3992.	1.4	11
54	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. <i>Blood</i> , 2014, 124, 4552-4552.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models. , 2015, , .		7
56	Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. <i>Clinical Cancer Research</i> , 2022, 28, 1268-1276.	7.0	7
57	Dimerizer-Mediated Regulation of Gene Expression. <i>Cold Spring Harbor Protocols</i> , 2012, 2012, pdb.top070128-pdb.top070128.	0.3	6
58	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012, 120, 3747-3747.	1.4	6
59	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2013, 122, 652-652.	1.4	6
60	Dimerizer-Mediated Regulation of Gene Expression In Vitro. <i>Cold Spring Harbor Protocols</i> , 2012, 2012, pdb.prot070136.	0.3	5
61	Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants. <i>Cancer Research</i> , 2015, 75, 2827-2827.	0.9	5
62	Assessment of the Safety and Biodistribution of a Regulated AAV2 Gene Transfer Vector after Delivery to Murine Submandibular Glands. <i>Toxicological Sciences</i> , 2011, 123, 247-255.	3.1	4
63	Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFR α and FGFR1. , 2012, , .		3
64	Rapamycin-regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer. <i>Molecular Therapy</i> , 0, , .	8.2	0